ERBB2 and breast carcinoma: Studies have demonstrated that HER2 ITH, as detected using HER2 GPA, is associated with therapeutic resistance to anti-HER2 neoadjuvant chemotherapy (NAC) in patients with HER2-positive breast cancer [30].